XEOMIN® Efficacy | Pediatric Chronic Sialorrhea

XEOMIN is the First and Only FDA-Approved Neuromodulator For Pediatric Patients With Chronic Sialorrhea

Significant and Sustained Reductions in Unstimulated Salivary Flow Rate (uSFR) From Baseline (Ages 6–17 Years) Over 16 weeks1*

Chart showing significant sustained reductions in unstimulated salivary flow rate. Pinch to zoom

Clinically Meaningful Improvement in Carer’s Global Impression of Change Scale (GICS) Ratings vs Placebo (Ages 6–17 Years)1

Chart showing improvement in carer's global impression of change scale ratings. Pinch to zoom

Sustained Improvements in GICS Scores Over 16 Weeks (Ages 6–17 Years)1

Chart showing sustained improvements in GICS score over time. Pinch to zoom

Patients who were 2–5 years old showed similar improvement in caregiver GICS scores as patients aged 6–17 years old1

Chart showing similar improvements in caregive GICS scores in patients aged 2 to 5 years old as patients aged 6 to 17 years old. Pinch to zoom

Reference

  1. XEOMIN® [Package insert]. Raleigh, NC: Merz Pharmaceuticals, LLC; 2020.